The global clinical next-generation sequencing (NGS) market, valued at USD 6.2 billion in 2024, is expected to reach USD 15.2 billion by 2032 with a 13.6% CAGR. Growth drivers include personalized ...

The global companion diagnostics market is set to surge from USD 7.03 Billion in 2024 to USD 22.83 Billion by 2034, driven by rising cancer prevalenc ...

Next-generation sequencing (NGS) has transformed immune profiling, enabling deeper characterization of disease mechanisms, ...

Panelists discuss how biomarker development in anal cancer remains limited with PD-L1 status not influencing treatment ...

QIAGEN expands NGS portfolio with launch of QIAseq xHYB Long Read Panels: Venlo, The Netherlands Thursday, July 24, 2025, 10:00 Hrs [IST] QIAGEN, a Netherlands-based holding compa ...

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

A global team mapped over 100,000 structural variants in human genomes by applying Oxford Nanopore long-read sequencing and a ...

Yemaachi Biotech, a pioneering genomics research company based in Ghana and Illumina , a global leader in sequencing ...

University of Kentucky Markey Cancer Center researchers have discovered a genetic biomarker that could help identify patients ...

Subtle differences in an mRNA sequence enables a ribosome to produce more or less of a certain protein. A new AI model called ...

Monoclonal antibodies are fundamental to modern biomedical research, therapeutic development, and diagnostic applications.

The roadmap was coauthored from key leaders of the Solana ecosystem and centers on ‘Application-Controlled Execution’ ...